SecBot SecBot

ALDX drug pipeline

$0.6939
+3.6% 1-day · Nov 17
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±31.6%
1-day, median of 3 events
IV rank
No data
No current options data
Rated drugs
1
1 bearish
Phase 3 trials
1
1 with results posted

Drugs

soonest catalyst first
▼ bearish
Impact
PhasePhase 2 (RP completed); Phase 3 (PVRL on hold)
Time to marketUncertain. The PVRL program is in regulatory limbo after the SPA withdrawal and IND transfer request. The RP program has Fast Track designation but no Phase 2/3 trial has been confirmed as initiated. Even under optimistic scenarios, any potential approval is likely several years away.

ADX-2191 methotrexate (intravitreal formulation) Updated Nov 12

What to watch

Watch for the FDA's decision on Aldeyra's jurisdiction transfer request for ADX-2191's IND, which will determine which division oversees the PVRL program and what development path will be required. Also monitor whether the planned Phase 2/3 trial in retinitis pigmentosa ever initiates, as that would provide a future catalyst. The company's cash runway and the reproxalap appeal outcome are broader factors affecting ALDX's ability to fund ADX-2191 development.

Bull case
  • ADX-2191 showed positive Phase 2 results in retinitis pigmentosa, with improvement from baseline in retinal function (Aldeyra press release, June 29, 2023).
  • The FDA granted Fast Track designation for ADX-2191 in retinitis pigmentosa in August 2025, which can expedite development and review.
  • The EMA granted Orphan Designation for ADX-2191 in both inherited retinal dystrophies (including RP) and primary large B-cell lymphomas (including PVRL) in 2025, providing market exclusivity benefits if approved.
Bear case
  • ADX-2191 received a Complete Response Letter from the FDA in June 2023 for PVRL, with the agency citing lack of substantial evidence of effectiveness (BioWorld, June 21, 2023).
  • On November 9, 2026, Aldeyra withdrew the Special Protocol Assessment agreement for ADX-2191 in PVRL and requested transfer of the IND to a different FDA division, creating significant regulatory uncertainty and putting the planned Phase 3 trial on hold indefinitely (SEC 8-K filed Nov 9, 2026).
  • The PVRL program now faces potential delays, redesign, or discontinuation; any redesigned trial may be larger, longer, more costly, and harder to enroll given the rarity of the disease.

Other drugs in filings and trials

no drug report yet
  • Reproxalap Last: PDUFA decision · Mar 16, 2026
  • ADX-629 (Open-label) 1 trial

Past FDA events & how the stock moved

3 events
DateDrugEvent1 day5 days
Mar 16, 2026ReproxalapPDUFA decision−69.9%−45.9%
Dec 16, 2025reproxalapNDA filed+31.6%+26.6%
Dec 16, 2025reproxalapPDUFA decision+31.6%+26.6%

Clinical trials

4 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
ADX-629A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)Phase 2Completed4Jun 18, 2025
ADX-629 (Open-label)A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)Phase 2Completed · results8Nov 21, 2023
ADX-2191A Study in Subjects With Retinitis PigmentosaPhase 2Completed · results8Jun 23, 2023
Reproxalap Ophthalmic Solution (0.25%)The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic ConjunctivitisPhase 3Completed · results131Apr 22, 2023